Gold prices edged higher; remain near $3,400/oz as Sept rate cut bets rise
SOUTHAMPTON, UK - Synairgen PLC (LON:SYNG), a firm specializing in respiratory drug development, today disclosed significant changes to its executive team, including a new CEO appointment, set to take effect from July 1, 2025. Richard Marsden will resign as CEO and board member but will continue to provide strategic guidance as a part-time Board Advisor. Joseph Colliver, the current CFO, will ascend to the CEO role, bringing a diverse business and financial background to the company’s leadership.
Mark Parry-Billings, who has served as Non-Executive Chairman since October 2024, will assume the position of Executive Chairman on the same date. His expanded role aims to utilize his extensive experience in pharma and biotech R&D to further advance Synairgen’s core program, particularly its investigational SNG001 treatment for viral pneumonia in mechanically-ventilated patients.
Dr. Parry-Billings expressed gratitude for Marsden’s two decades of leadership and contributions to Synairgen, noting the importance of the transition for the company’s future. He also conveyed confidence in Colliver’s capabilities to lead Synairgen through its next phase of development.
These leadership transitions come at a pivotal time for Synairgen, as the company focuses on addressing the high unmet medical needs of patients with viral pneumonia. The information is based on a press release statement from Synairgen PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.